AHA Coding Clinic® for ICD-9 - 2005 Issue 4; VOLUMES 1 AND 2 NEW/REVISED CODES
Noxious Influences Affecting Fetus or Newborn
Effective October 1, 2005, two new codes have been created to separately report anticonvulsants (760.77) and antimetabolic agents (760.78) as substances affecting fetus or newborn via placenta or breast milk. Several substances have been recognized to affect fetal development when the mother is exposed to the substance during pregnancy. At the request of the American College of Medical Genetics, subcategory 760.7 has been expanded to track the effects of anticonvulsants and antimetabolic agents. While relatively uncommon, approximately 1% to 3% of birth defects are related to medications taken by the mother while pregnant. The teratogenic effect...
Subscribe or sign in to view the full article.
Article Overview
This article covers an ICD-9-CM update involving maternal substance exposures that can affect a fetus or newborn, with emphasis on the expansion of subcategory 760.7 and the addition of new substance-specific codes. It is relevant to coders, clinical documentation teams, and compliance staff who need to understand the scope of the classification update and the types of substances referenced. The article also includes a brief coding scenario involving a newborn diagnosis tied to maternal treatment exposure.
Why This Topic Matters
Accurate reporting of maternal exposure-related conditions depends on understanding how the classification changed and which substance categories are separately tracked. The topic is important for medical coders and auditors working with perinatal, newborn, and maternal documentation.
Article Sections
-
Effective date and code expansion
Introduces the effective date of the update and the expansion of the fetal/newborn exposure category. It explains the general purpose of separating certain substance exposures for tracking.
-
Background on fetal effects of maternal substance exposure
Summarizes the broader clinical context for maternal exposure during pregnancy and its potential effects on fetal development. It also references general sources and research discussed in the article.
-
Anticonvulsants and antimetabolic agents
Describes the substance groups added in the update and notes examples mentioned in the article. The section places those groups within the larger exposure category.
-
Clinical example and coding question
Presents a newborn scenario involving maternal treatment exposure and asks how the case should be coded. The section shows how the article applies the classification update to a practical documentation example.
What You Will Learn
- How the article frames an ICD-9-CM update for fetal and newborn exposure categories
- Which broad substance groups are highlighted in the update
- Why maternal exposure topics are relevant in newborn and perinatal coding
- How the article connects a clinical scenario to the classification change
Who Should Read This
- Medical coders
- Coding auditors
- Clinical documentation specialists
- Compliance staff
- Revenue cycle professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com